Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Goode

Showing results (161-170 of 164) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 164 results.
Nature Medicine|June 3, 2020
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Nature Medicine|March 6, 2019
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Cancer Cell|July 12, 2017
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic CancerSurendra K Shukla, Vinee Purohit, Kamiya Mehla, et al.
Cancer Cell|September 13, 2017
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic CancerSurendra K Shukla, Vinee Purohit, Kamiya Mehla, et al.
Pageof 17

Showing results (161-170 of 164) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 164 results.
Nature Medicine|June 3, 2020
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Nature Medicine|March 6, 2019
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Cancer Cell|July 12, 2017
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic CancerSurendra K Shukla, Vinee Purohit, Kamiya Mehla, et al.
Cancer Cell|September 13, 2017
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic CancerSurendra K Shukla, Vinee Purohit, Kamiya Mehla, et al.
Pageof 17